Because benign prostatic hyperplasia (BPH) may be in¯uenced by plasma steroid hormones, we examined their relation in the Health Professionals Follow-up Study. In 1993±1995, 18,000 cohort members provided blood. We selected as cases men who had had surgery for BPH (n 174) or who scored 20±35 points (n 126) on the American Urological Association index of severity of lower urinary tract symptoms. Cases were matched by age to men who scored 3 points and without an enlarged prostate or elevated prostate-speci®c antigen. We estimated the odds ratio (OR) of BPH surgery and severe lower urinary tract symptoms for plasma testosterone (T), dihydrotestosterone (DHT), androstanediol glucuronide (AAG), estradiol (E2), and sex hormone binding globulin (SHBG) in multivariable conditional logistic regression models.
Introduction
Androgens are clearly important in the maintenance of benign prostatic hyperplasia (BPH) as demonstrated by the reduction in size of an enlarged prostate with androgen deprivation 1 and treatment with 5a-reductase type 2 inhibitors.
2 However, neither plasma levels of testosterone (T) and dihydrotestosterone (DHT), nor other steroid hormones, such as estradiol (E2), within normal ranges have been consistently related to the risk of developing BPH. 3±17 This inconsistency may be attributed to small samples sizes, inadequate assessment of BPH, and failure to control for sex hormone binding globulin (SHBG) or other potentially confounding factors. We addressed these concerns in this study of the relations of plasma steroid hormones with BPH among 300 men who underwent surgery for BPH or who had severe lower urinary tract symptoms and 300 age-matched controls drawn from a large cohort study reported herein.
Materials and methods

Study population
Cases and controls were selected from among participants in the Health Professionals Follow-up Study, a prospective cohort study of 51,529 men aged 40±75 y at enrollment in 1986. At baseline and every 2 y subsequently the men provided information on demographics, diet, lifestyle and medical history. In 1993±1995 approximately 18,000 of the men provided a blood specimen. Specimens were collected in tubes containing sodium EDTA and chilled during transport by overnight carrier. On arrival, they were centrifuged, aliquoted into plasma, erythrocytes and buffy coat, and stored in liquid nitrogen freezers.
Case de®nition
On the 1988, 1990, 1992 and 1994 questionnaires we asked participants whether they had undergone surgery for prostatic enlargement. Self report of surgery for BPH has been validated. 18 At the time of blood draw the men completed a questionnaire that included the American Urological Association symptom index.
19 Men without surgery for BPH whose symptom scores were 20 points out of 35 were considered to have severe lower urinary tract symptoms.
19 Also on the questionnaire completed at the time of blood draw, we asked whether they had ever had a diagnosis of enlarged prostate detected by digital-rectal examination or an elevated prostate-speci®c antigen.
Selection of cases and controls
We excluded men with cancer (except nonmelanoma skin cancer) before 1986, a diagnosis of prostate cancer up to 1996, an inadequate diet report in 1986 or 1994, or who did not provide body habitus information in 1988. For controls and symptomatic cases, men were ineligible if at the time of blood draw they reported current use of medications for BPH. We excluded these men because of the possible in¯uence of these medications on circulating hormone levels and on frequency of lower urinary tract symptoms. The 300 cases were as follows: all men who reported having had BPH surgery during the same year as (n 86) or following (n 73, up to 3 y later) the date of blood draw, a random sample of 15 men who had had BPH surgery during the year before blood draw, and all 126 men who did not report having had surgery for BPH, but who had severe lower urinary symptoms at the time of blood draw. Controls were men who had not had BPH surgery, whose lower urinary tract symptom score was low ( 2 for 281 and 3 for 19), and did not have an enlarged prostate or elevated prostate-speci®c antigen. Cases (n 300) and controls (n 300) were matched on baseline age within 2 y, the time of day and the season of the year during which the blood was drawn, and year of blood draw within 1 y.
Plasma steroid hormone assays
Plasma concentrations were measured as follows: total T and E2, kits from Diagnostic Products Corporation (Los Angeles, CA); DHT, radioimmunoassay after celite column chromatography; 20 androstanediol glucuronide (AAG), radioimmunoassay kit from Diagnostic Systems Laboratory (Webster, TX); and SHBG radioimmunometric kit from Diagnostic Systems Laboratory. Mean intrapair coef®cients of variation were 5.5% for total T, 32.8% for DHT, 9.2% for AAG, 26.8% for E2, and 8.1% for SHBG.
Statistical analysis
We tested for differences between cases and controls in means and proportions of demographic and lifestyle factors using the Wilcoxon sign rank test or the exact equivalent of McNemar's test. We estimated odds ratios (OR) and 95% con®dence intervals for the relations between steroid hormones and BPH from conditional logistic regression models. Because they are correlated, we mutually adjusted for steroid hormones and SHBG. In separate analyses, we further controlled for other baseline BPH risk factors that may in¯uence steroid hormone levels, including baseline values for smoking status, raceaethnicity, alcohol intake, body mass index, and physical activity. All analyses were done in SAS version 6.12 (SAS Institute, Cary, NC).
Results
Cases and controls did not differ signi®cantly on body mass index, physical activity, percentage of calories from fat, or total energy intake ( Table 1) , but cases were more likely to be of Southern European heritage, less likely to be current smokers, and consumed less alcohol. Cases had a higher plasma AAG concentration and slightly higher ratio of DHT to T than controls, although the difference was not statistically signi®cant (Table 1) . When not mutually adjusting for plasma steroid hormones or the demographic, diet and lifestyle covariates, men in the middle (OR 1X34) and top (OR 1X44) tertiles of AAG concentration were at increased risk for BPH surgeryasevere lower urinary tract symptoms compared with men in the bottom tertile (P-trend 0X08). Compared to the bottom tertile of plasma E2, men in the middle (OR 0X63) and top (OR 0X72) tertiles had a lower risk of BPH surgeryasymptoms, however the trend was not monotonically decreasing (P-trend 0X3). There were no clear associations of BPH surgeryasymptoms with plasma total T, DHT or SHBG. There was a direct relation between BPH surgeryasymptoms and the ratio of AAG to T, a possible indicator of intraprostatic availability of DHT (compared to tertile 1, tertile 2: OR 1X17; tertile 3: OR 1X48; P-trend 0X07).
Simultaneously adjusting for total T, AAG, SHBG, DHT and E2 accentuated the positive relation of AAG and the inverse relation of E2 with risk of BPH surgeryasymptoms ( Table 2) . As in the age-adjusted models, no relations between T, DHT and SHBG with risk were evident (Table 2) . Also, controlling for SHBG, DHT and E2, the association between AAG to T ratio (compared to tertile 1, tertile 2: OR 1X24; tertile 3: OR 1X64; P-trend 0X05) and risk persisted. The results were similar when excluding men whose surgery for BPH was done prior to or during the same year as providing a blood specimen. After further controlling for potential BPH risk factors, the ORs by tertile of steroid hormone concentration were not appreciably altered (Table 2) , with the exception of the ratio of AAG to T, for which the ORs were greater (compared to tertile 1, tertile 2: OR 1X38; tertile 3: OR 1X91; P-trend 0X02).
Risk of severe lower urinary tract symptoms (excluding BPH surgery) was increased in the middle (OR 2X07) and upper (OR 2X36) tertiles of AAG compared to the lowest tertile, after mutually controlling for steroid hormones, SHBG and the potential BPH risk factors (P-trend 0X05). Risk of BPH surgery also modestly increased with increasing tertiles of AAG (compared to tertile 1, tertile 2: OR 1X24; tertile 3: OR 1X54; P-trend 0X18). Risks of both severe symptoms and BPH surgery were lower among men who had higher E2, although the relations were not linearly decreasing.
The ORs for ever having had a diagnosis of enlarged prostate among the severe symptomatic cases (n 88) were elevated in the middle and upper tertiles of AAG and DHT (Table 3 ). Including the ratio of DHT to T in the model and controlling for AAG, SHBG, E2, indicated a lower risk of enlarged prostate only in the lowest tertile of DHT to T ratio (compared to tertile 1, tertile 2: OR 3X13; tertile 3: OR 2X03; P-trend 0X5). The AAG to T ratio Estimated from a conditional logistic regression model and adjusted for the other steroid hormones, SHBG, raceaethnicity (Southern European, Scandinavian, other vs other Caucasian), cigarette smoking status (past, current vs never), alcohol consumption (continuous), body mass index (continuous) and physical activity (continuous). was directly related to enlarged prostate risk after adjusting for the other steroid hormones (compared to tertile 1, tertile 2: OR 1X82; tertile 3: OR 3X12; P-trend 0X04).
Comment
We observed that men with higher plasma AAG, a DHT metabolite, and perhaps lower E2 levels were at an increased risk for BPH surgery and severe lower urinary tract symptoms. In addition, plasma DHT and the DHT to T and AAG to T ratios were related to history of enlarged prostate in men with severe lower urinary tract symptoms. Our ®ndings suggest that intraprostatic DHT and E2 likely play opposing roles in the etiology of BPH, particularly in prostatic enlargement.
Findings from previous studies of BPH and plasma steroid hormone concentrations have not been consistent.
3À17 One of the largest studies, which consisted of 320 mostly White Americans who underwent BPH surgery up to 9 y after providing a blood specimen and 320 age-matched controls, noted no clear associations between androstenedione, T, DHT, E2, estrone or DHT to T ratio in univariate analyses.
15 AAG and SHBG were not measured. However, after adjusting for exercise frequency, alcohol use and diastolic blood pressure, and simultaneously for E2, estrone and DHT to T ratio, a strongly positive association between E2 and risk of BPH surgery emerged, especially among men with low T levels; DHT to T ratio remained unrelated to risk of BPH surgery. A recent Greek study examined hormone levels in 52 cases who underwent surgery for BPH and were histologically con®rmed and 52 age-matched controls; no clear associations between BPH and T or E2 were found in multivariate models simultaneously adjusting for anthropometric factors and steroid hormones.
17 Possible explanations for the disparate ®ndings among the other studies examining steroid hormones in relation to BPH include inadequate power due to small sample sizes, dissimilar age distributions among cases and controls not accounted for in the analyses (eg cases tended to be older and older men have higher E2, lower T), determination of steroid hormone levels at different points in the natural history of BPH, and inclusion of men with differing predominance of underlying pathologies (ie dynamic vs static component). Importantly, many of these studies did not mutually adjust for hormones and SHBG, which modulates the bioavailability of androgens, and to a lesser extent estrogens, 21 and nor did they account for factors that independently in¯uence steroid hormone levels and risk for BPH (eg smoking and alcohol consumption).
BPH is a complex, multifactorial condition that we classi®ed into several subgroups: BPH surgery, severe lower urinary tract symptoms, and enlarged prostate among men with severe lower urinary tract symptoms. BPH surgery is usually performed in men with severe lower urinary tract symptoms and a palpably enlarged prostate. Because some men may have a propensity to seek surgical intervention, the combined endpoint of BPH surgery and lower urinary tract symptoms is preferable for examining BPH in relation to potential risk factors to avoid bias. We observed that the magnitudes of the relations of AAG and E2 with severe lower urinary tract symptoms were stronger than for BPH surgery, possibly because the steroid hormones were assessed more proximal to the process of BPH development.
Our use of the American Urological Association symptom index in a general population of men is not speci®c 19 and could have led to the misclassi®cation of some men with other urinary problems as BPH cases. Nevertheless, our ®ndings for plasma AAG (directly associated) and E2 (nonlinearly inversely associated) were in the same directions among the 126 men with severe lower urinary tract symptoms and the 174 men who underwent BPH surgery. Eighty-eight of the 126 men with severe lower urinary tract symptoms as assessed by this index also reported having had an enlarged prostate detected, and thus they are those most likely to have underlying BPH. The ®nd-ings for this subset were also in the same direction for men who had surgery for BPH and for all symptomatic men irrespective of history of prostate enlargement. The similarity in ®ndings supports that it is unlikely that there was extensive misclassi®cation of men without BPH among those with severe lower urinary tract symptoms.
Intraprostatic concentrations of steroid hormones are probably most relevant etiologically. The representativeness of plasma for tissue levels is not equivalent among those measured and, therefore, the degree of exposure misclassi®cation and extent of attenuation of the underlying steroid hormone and BPH relations may differ by hormone. For example, because DHT is produced peripherally through the action of 5a-reductase type 1, as well as intraprostatically by 5a-reductase type 2, plasma DHT re¯ects the balance of production at these sites. Additionally, a single measurement may not represent typical or time-averaged levels because of daily pulsatile secretion, day-to-day variation, and variation with aging. The period during life (in utero, early life, puberty and throughout adulthood) when hormone levels are important for BPH development and progression is unknown. Blood was obtained concurrently with assessment of lower urinary tract symptoms, and although blood was obtained from the majority of surgery cases prior to surgery, these men were likely to have been symptomatic for many years before the blood sample was taken. If steroid hormone production, metabolism and clearance are altered in the hyperplastic prostate, then our crosssectional ®ndings would be pertinent for BPH maintenance rather than BPH development. Nondifferential measurement error for DHT and E2 probably led to attenuated estimates of their relations with BPH. This source of error may explain why plasma AAG, which was measured with good precision, but may be only modestly correlated with plasma DHT, better predicts BPH risk than does DHT. Alternatively, plasma AAG may be a better time-integrated measure of intraprostatic DHT than plasma DHT.
Since both BPH prevalence and the E2 to T ratio increase with age, it has been hypothesized that the increasing estrogen to androgen balance contributes to the development and sustainment of this prostate condition. Our results are not compatible with this hypothesis, since we found that in mid-to late-adulthood higher E2 level is inversely related, whereas T metabolites, although not T itself, are positively related to BPH. During puberty androgens and growth factors stimulate prostate maturation. Whether steroid hormone levels measured among these men during adulthood captures their levels in puberty or an earlier in¯uential time point is unknown.
Circulating levels of AAG are lower in men with inherited 5a-reductase type 2 de®ciency 22 or who are treated with ®nasteride, a 5a-reductase inhibitor, 23 presumably because of lower DHT concentrations. Thus, it would be expected that men with high intraprostatic AAG relative to T would be at an increased risk for BPH. The AAG to T ratio in plasma was in fact moderately positively associated with BPH overall, and even more strongly associated with enlarged prostate. Despite imprecision in our measurement of plasma DHT, the ratio of AAG to DHT was also moderately associated with enlarged prostate (not shown). The androgen receptor transactivational activity induced by binding to DHT in the prostate is substantially greater than for T. As would be predicted, men with a higher plasma DHT to T ratio were at an increased risk for enlarged prostate.
Conclusions
Androgens, estrogens and SHBG, measured as peripheral circulating levels, appear to in¯uence the maintenance and possibly the development of BPH. Improved measures of steroid hormone levels during multiple periods of life in the prostate and their simultaneous consideration, as well as examining speci®c underlying BPH pathologies (prostatic enlargement vs prostatic tone) will aid in further clarifying the contribution of steroid hormones to BPH development and progression.
